Triptorelin (Trelstar/Triptodur) - Complete Research Paper

1. Summary

Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist used for the palliative treatment of advanced prostate cancer and the management of central precocious puberty (CPP) in children. Developed by Debiopharm Group and marketed in the United States primarily under the brand names Trelstar (prostate cancer) and Triptodur (CPP), triptorelin received initial FDA approval in 2000.

The drug functions identically to other GnRH agonists through initial pituitary stimulation followed by receptor downregulation and sustained suppression of the hypothalamic-pituitary-gonadal axis. This results in castrate levels of testosterone in men (used therapeutically in prostate cancer) or suppression of ovarian function in women and children (used in CPP and endometriosis).

Triptorelin is distinguished by its comprehensive range of depot formulations, offering 1-month (3.75 mg), 3-month (11.25 mg), and 6-month (22.5 mg) dosing options. The 6-month formulation (Trelstar 22.5 mg, approved March 2010) was the first intramuscular GnRH agonist available with semi-annual dosing for prostate cancer, offering significant convenience for long-term maintenance therapy.

Clinical trials demonstrate excellent efficacy, with 97.5% of prostate cancer patients achieving castrate testosterone levels by day 29, and 98%+ maintaining castration through month 12. Mean testosterone levels of 12.8 ng/dL (well below the 50 ng/dL castrate threshold) and median PSA reductions of 96.4% have been documented.

For pediatric CPP, Triptodur (22.5 mg every 24 weeks) became the first six-month dosing option available, approved in 2017. This extended-release formulation significantly reduces the burden of frequent injections for children requiring long-term GnRH agonist therapy.

Common adverse effects include hot flashes (>70%), injection site reactions (pain 45%, redness 14%), and symptoms related to hormone suppression. Safety warnings include tumor flare risk in prostate cancer, pseudotumor cerebri in pediatric patients, and postmarketing reports of convulsions and psychiatric symptoms.

2. Goal Archetype Integration

Primary Classification: GnRH Agonist - Hormonal Suppression (Chemical Castration)

Goal Archetype Mapping:

Clinical Goal Scenarios:

Scenario 1: Advanced Prostate Cancer - Palliative Treatment

• Goal: Achieve and maintain castrate testosterone levels to slow tumor growth
• Triptorelin Advantage: 6-month depot option (Trelstar 22.5 mg) reduces clinic visits
• Outcome: >97% achieve castration by day 29; median testosterone 12.8 ng/dL

Scenario 2: Central Precocious Puberty - Pediatric Management

• Goal: Arrest premature puberty to preserve adult height potential
• Triptorelin Advantage: Triptodur offers first 6-month pediatric dosing option
• Outcome: Pubertal regression, normalized growth velocity, preserved final height

Scenario 3: High-Risk Prostate Cancer with Spinal Metastases

• Goal: Testosterone suppression while managing flare risk
• Triptorelin Consideration: Initial testosterone surge requires antiandrogen cover
• Alternative: Consider GnRH antagonist (degarelix) if flare risk unacceptable

Scenario 4: Endometriosis - Pain Management (Off-Label)

• Goal: Hypoestrogenic state to induce endometriotic tissue atrophy
• Triptorelin Application: 3.75 mg monthly for up to 6 months
• Limitation: Bone density concerns limit treatment duration

Scenario 5: Gender-Affirming Care - Puberty Suppression

• Goal: Reversible suppression of endogenous puberty
• Triptorelin Use: Depot formulations provide consistent suppression
• Outcome: Prevents unwanted secondary sex characteristics; fully reversible

Agonist Flare Consideration:

DosingIQ Goal Integration:

• Prostate cancer protocols should offer 1-, 3-, or 6-month formulation choice based on patient preference and compliance factors
• CPP protocols should highlight Triptodur as the longest-acting pediatric option
• Flare assessment should be documented before initiation in prostate cancer
• Bone health monitoring should be integrated for all long-term users

3. Mechanism of Action

Triptorelin is a synthetic analog of naturally occurring gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). The molecule is a decapeptide with amino acid substitutions that confer enhanced receptor binding affinity and resistance to enzymatic degradation, resulting in extended biological activity compared to native GnRH.

Molecular Structure:

• Sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
• Key Modification: D-Tryptophan at position 6 (vs. Glycine in native GnRH)
• Molecular Weight: 1,311.46 Da
• Effect: 13-fold increased potency and resistance to enzymatic degradation

Initial Agonist Phase (Flare Phenomenon): Upon initial administration, triptorelin binds to and activates GnRH receptors in the anterior pituitary gland, causing robust stimulation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release. This produces a transient surge in gonadal hormone production:

In Males:

• Testosterone levels may increase 50-100% above baseline during weeks 1-2
• This "flare" can temporarily worsen prostate cancer symptoms
• Bone pain, urinary obstruction, and spinal cord compression may occur
• Antiandrogen co-therapy recommended during initiation

In Females/Children:

• Transient estradiol elevation
• In CPP patients, initial worsening of pubertal signs may occur
• Menstrual spotting possible in girls during first 1-2 months

Sustained Suppression Phase: Continuous GnRH receptor stimulation leads to receptor desensitization and downregulation in pituitary gonadotroph cells. By weeks 2-4:

• LH and FSH secretion become profoundly suppressed
• Serum testosterone falls to castrate levels (<50 ng/dL) in males
• Serum estradiol decreases to prepubertal/postmenopausal levels in females
• Ovarian function ceases; amenorrhea develops in premenopausal women

Downstream Therapeutic Effects:

Prostate Cancer:

• Androgen deprivation halts testosterone-dependent tumor cell proliferation
• PSA levels decline as marker of therapeutic response
• Disease progression may be delayed for months to years

Central Precocious Puberty:

• Arrests premature hypothalamic-pituitary-gonadal activation
• Pubertal progression halts; regression of secondary sexual characteristics may occur
• Adult height potential preserved by preventing premature epiphyseal fusion
• Effects fully reversible upon treatment discontinuation

Endometriosis (Off-label in US):

• Hypoestrogenic state induces atrophy of ectopic endometrial tissue
• Pain relief and reduction of endometriotic lesions
• Bone density concerns limit treatment duration

3. FDA-Approved Indications

Advanced Prostate Cancer (Trelstar - All Formulations):

• Palliative treatment of advanced prostate cancer
• Approved formulations: 3.75 mg (monthly), 11.25 mg (3-month), 22.5 mg (6-month)
• Initial FDA approval: 2000 (1-month and 3-month); 2010 (6-month)
• Can be used as monotherapy or combined with antiandrogen (combined androgen blockade)
• Neoadjuvant/adjuvant to radiation therapy for locally advanced disease

Central Precocious Puberty (Triptodur):

• Treatment of children 2 years of age or older with central precocious puberty
• Triptodur 22.5 mg: FDA approved October 2017
• First 6-month dosing option for pediatric CPP
• Indicated for both girls and boys with CPP
• Diagnosis must confirm central (gonadotropin-dependent) origin

Indications Approved Outside the US:

• Endometriosis (approved in Europe and other regions)
• Uterine fibroids (preoperative treatment)
• Breast cancer (premenopausal, hormone receptor-positive)
• Assisted reproduction (pituitary suppression for IVF protocols)
• Gender dysphoria/puberty suppression (varies by country)

Off-Label Uses in the US:

• Endometriosis management
• In vitro fertilization protocols
• Gender-affirming puberty suppression
• Premenopausal breast cancer (OFS, though goserelin has FDA approval)
• Chemical castration for paraphilias (mandated in some jurisdictions)

4. Dosing and Administration

Available Formulations:

Trelstar (Prostate Cancer):

• Trelstar 3.75 mg: Intramuscular injection every 4 weeks
• Trelstar 11.25 mg: Intramuscular injection every 12 weeks
• Trelstar 22.5 mg: Intramuscular injection every 24 weeks

Triptodur (Central Precocious Puberty):

• Triptodur 22.5 mg: Intramuscular injection every 24 weeks
• For children ≥2 years of age

Administration Technique:

• Route: Intramuscular (IM) injection only
• Reconstitution: Mix lyophilized powder with provided sterile water/diluent
• Site: Gluteal muscle (deltoid may be acceptable for some formulations)
• Must be administered by healthcare professional
• Inject immediately after reconstitution

Prostate Cancer Dosing:

• Initial dose: Any of the three formulations based on patient/physician preference
• Consider concurrent antiandrogen for first 2-4 weeks to prevent flare
• Continue indefinitely or until disease progression
• All formulations equally effective when administered on schedule

Central Precocious Puberty Dosing:

• Triptodur 22.5 mg every 24 weeks
• Starting criteria: Confirmed diagnosis of CPP, age ≥2 years
• Discontinuation: When appropriate to allow pubertal progression (typically age 11-12 in girls, 12-13 in boys)
• Monitor for adequate suppression through LH, FSH, and sex steroid levels

Timing Considerations:

• Administer on or before the scheduled date to maintain continuous suppression
• If dose significantly delayed, testosterone/estradiol may rise ("escape")
• Prostate cancer: PSA monitoring guides dose timing compliance
• CPP: Physical exam and hormone levels monitor suppression

Conversion Between Formulations:

• Can switch between 1-month, 3-month, and 6-month formulations
• Time new formulation based on when next dose of previous formulation would be due
• No loading dose required when switching

5. Age-Stratified Dosing

Overview: Triptorelin uses fixed dosing based on formulation selection (3.75 mg monthly, 11.25 mg quarterly, 22.5 mg semi-annually for adults; 22.5 mg semi-annually for pediatric CPP). Dosing does not vary by age or weight, but monitoring intensity and adverse event management require age-specific considerations.

Pediatric Patients (Central Precocious Puberty)

Age 2-5 Years (Young Children with CPP):

Dosing:

• Triptodur 22.5 mg IM every 24 weeks
• No weight-based adjustment
• Same formulation as older children

Considerations:

• Youngest approved patient population
• May require sedation or distraction techniques for injection
• Parental anxiety management important
• Monitor closely for behavioral changes (more difficult to assess in younger children)
• Pseudotumor cerebri risk - monitor for headaches, vision changes

Monitoring Adjustments:

• More frequent clinical assessments initially (every 2-3 months)
• Bone age every 6 months
• Height velocity critical for assessing response
• LH stimulation testing if suppression questioned

Age 6-8 Years (School-Age Children with CPP):

Dosing:

• Triptodur 22.5 mg IM every 24 weeks
• Standard pediatric protocol

Considerations:

• Typical presentation age for girls with CPP
• School performance and social adjustment monitoring
• Psychiatric symptoms (mood changes, irritability) require attention
• Explain treatment at age-appropriate level

Monitoring Adjustments:

• Standard CPP monitoring intervals
• Bone age every 6-12 months
• Tanner staging assessment each visit
• Growth velocity tracking

Age 9-12 Years (Preadolescent/Approaching Normal Puberty):

Dosing:

• Triptodur 22.5 mg IM every 24 weeks
• Continue until appropriate age for natural puberty

Considerations:

• Typical presentation age for boys with CPP
• Approaching age of treatment discontinuation
• Transition planning important
• Discuss what to expect when treatment stops

Monitoring Adjustments:

• Treatment duration decisions become relevant
• Girls: Consider discontinuation around age 11
• Boys: Consider discontinuation around age 12-13
• Bone age guides discontinuation timing

Adult Patients (Prostate Cancer)

Age 50-64 Years (Younger Prostate Cancer Patients):

Dosing:

• Any formulation: 3.75 mg monthly, 11.25 mg quarterly, or 22.5 mg semi-annually
• No dose adjustment for age

Considerations:

• Less common patient population
• May have longer anticipated treatment duration
• More likely to be sexually active - erectile dysfunction discussion important
• Career and quality of life impact more prominent
• Cardiovascular prevention strategies essential early

Monitoring Adjustments:

• Aggressive cardiovascular risk assessment
• Early baseline DEXA recommended
• HbA1c and lipid monitoring every 6 months initially
• Mental health screening important

Age 65-74 Years (Typical Prostate Cancer Population):

Dosing:

• Any formulation based on patient/physician preference
• 6-month formulation often preferred for convenience

Considerations:

• Majority of prostate cancer patients in this age range
• Most extensively studied population in clinical trials
• Balance oncologic benefit with quality of life
• Cardiovascular comorbidities common

Monitoring Adjustments:

• Standard ADT monitoring protocol
• Annual DEXA scans
• Metabolic monitoring every 6-12 months
• Cardiovascular assessment per guidelines

Age 75-84 Years (Elderly Prostate Cancer Patients):

Dosing:

• Any formulation; 6-month option reduces clinic visits
• No dose reduction for age alone

Considerations:

• Higher baseline fracture risk
• Polypharmacy common - medication review essential
• Falls prevention program recommended
• Cognitive effects of ADT may be more pronounced
• Competing mortality considerations

Monitoring Adjustments:

• More frequent bone density assessment
• Cognitive function screening
• Medication reconciliation each visit
• Lower threshold for bone-protective therapy initiation
• Quality of life emphasis

Age 85+ Years (Very Elderly):

Dosing:

• Standard dosing if treatment indicated
• 6-month formulation minimizes healthcare visits

Considerations:

• Individual risk-benefit assessment essential
• Life expectancy considerations for treatment duration
• Caregiver involvement in decision-making
• Goals of care discussions important
• May prefer observation over treatment in some cases

Monitoring Adjustments:

• Simplified monitoring appropriate to goals
• Focus on symptom management
• Functional status assessment
• Fall risk assessment critical
• Consider palliative care integration

Age-Related Adverse Event Risk Profile

Age-Specific Bone Protection Recommendations

6. Pharmacokinetics

Absorption:

• Route: Intramuscular depot injection (extended-release)
• Bioavailability: Essentially 100% from IM depot
• Time to peak concentration: Variable based on formulation
  • 3.75 mg: Peak at 1-3 hours post-injection
  • 11.25 mg: Sustained release over 12 weeks
  • 22.5 mg: Sustained release over 24 weeks
• Peak plasma concentration (Cmax): ~28.4 ng/mL (3.75 mg formulation)

Distribution:

• Volume of distribution: 30-33 L
• Protein binding: Not extensively bound; limited data
• Tissue distribution: Primarily pituitary gland (target organ)
• Does not significantly cross blood-brain barrier

Metabolism:

• Metabolic pathway: Enzymatic degradation by peptidases in liver, kidney, and plasma
• No hepatic cytochrome P450 involvement
• Metabolites: Unknown; presumed inactive peptide fragments
• No active metabolites identified

Elimination:

• Terminal half-life: 2.8-4.2 hours (after depot release)
• Total body clearance: 211 mL/min
• Excretion: Primarily renal (42% as intact drug and metabolites)
• Hepatic excretion: 12% in feces

Depot Pharmacokinetics:

• 3.75 mg formulation: Maintains castrate testosterone for 28 days
• 11.25 mg formulation: Maintains castration for 84 days (12 weeks)
• 22.5 mg formulation: Maintains castration for 168-182 days (24 weeks)
• Steady-state: Achieved after 1-2 dosing cycles

Clinical Pharmacodynamics:

• Testosterone suppression to <50 ng/dL:
  • 3.75 mg: 91.2% at day 29, 97.7% at day 57
  • 22.5 mg: 97.5% at day 29, >98% at months 6 and 12
• Mean testosterone on 22.5 mg: 12.8 ng/dL (well below castrate)
• PSA reduction: Median 96.4% at end of study

Special Populations:

• Renal impairment: No formal studies; caution advised
• Hepatic impairment: No formal studies; peptide metabolism likely preserved
• Pediatric: Same mechanism; pharmacokinetics similar in children ≥2 years
• Elderly: No dose adjustment; most prostate cancer patients are elderly
• Body weight: Standard dosing regardless of weight

6. Side Effects and Adverse Reactions

Very Common (>10% incidence):

Vasomotor Symptoms:

• Hot flashes/flushes: >70% (most frequently reported adverse reaction)
• Night sweats: 20-35%

Injection Site Reactions:

• Pain at injection site: 45%
• Redness/erythema: 14%
• Pruritus: 2.3%
• Swelling/induration: 2.3%

Hormonal Suppression Effects:

• Sexual dysfunction: 15-25% (erectile dysfunction, decreased libido)
• Mood changes/emotional lability: 10-20%
• Fatigue/asthenia: 10-15%

Common (1-10% incidence):

Musculoskeletal:

• Bone pain: 5-13% (may indicate tumor flare in prostate cancer)
• Skeletal pain/myalgia: 5-10%
• Arthralgia: 3-6%
• Leg pain/edema: 4-8%

Neurological:

• Headache: 5-10%
• Dizziness: 3-5%
• Paresthesias: 2-4%

Gastrointestinal:

• Nausea: 3-8%
• Vomiting: 2-4%
• Diarrhea: 1-3%

Cardiovascular:

• Hypertension: 4-6%
• Peripheral edema: 3-6%

Urological:

• Urinary symptoms (dysuria, frequency, retention): 2-5%
• May worsen initially with tumor flare

Serious Adverse Reactions:

Tumor Flare (Prostate Cancer):

• Worsening symptoms during first 2-3 weeks
• Bone pain exacerbation
• Spinal cord compression risk with vertebral metastases
• Urinary obstruction, acute retention
• Prevention: Concurrent antiandrogen therapy

Cardiovascular Events:

• FDA class warning (2010): Increased diabetes, MI, stroke, sudden death risk
• QT prolongation reported
• Risk increases with treatment duration and pre-existing CV disease

Pseudotumor Cerebri (Pediatric CPP):

• Idiopathic intracranial hypertension reported with GnRH agonists
• Symptoms: Headache, vision changes (blurred, double, loss)
• Pain behind eye, ringing in ears, nausea, dizziness
• Requires prompt ophthalmologic evaluation

Convulsions (Postmarketing):

• Reported in patients with and without predisposing factors
• Risk factors: History of seizures, epilepsy, CNS anomalies
• Cerebrovascular disorders, brain tumors
• Concurrent medications that lower seizure threshold

Psychiatric Events (Postmarketing):

• Emotional lability (crying, irritability, impatience)
• Anger and aggression
• Depression
• More prominent in pediatric population

Allergic/Hypersensitivity:

• Anaphylactic reactions (rare)
• Angioedema
• Urticaria

7. Drug Interactions

Clinically Significant Interactions:

QT-Prolonging Medications:

• Triptorelin may contribute to QT interval prolongation
• Use caution with other QT-prolonging agents:
  • Antiarrhythmics (amiodarone, sotalol, quinidine)
  • Antipsychotics (haloperidol, thioridazine, ziprasidone)
  • Fluoroquinolones (moxifloxacin)
  • Macrolide antibiotics
  • Methadone
• Baseline and periodic ECG monitoring recommended

Hyperprolactinemic Drugs:

• Dopamine antagonists may theoretically affect pituitary response
• Antipsychotics, metoclopramide
• Clinical significance uncertain

Seizure Threshold-Lowering Drugs:

• Concurrent use may increase convulsion risk
• Bupropion, tramadol, certain antipsychotics
• Monitor closely in patients on these medications

Moderate Interactions:

Hypoglycemic Agents:

• Androgen deprivation associated with insulin resistance
• May reduce effectiveness of diabetes medications
• Monitor blood glucose; adjust doses as needed

Anticoagulants:

• Theoretical interaction (case reports with other GnRH agonists)
• Monitor INR in warfarin patients

Drugs with No Significant Interactions:

No CYP450 Interactions:

• Triptorelin metabolized by peptidases, not hepatic enzymes
• Safe with CYP substrates, inhibitors, and inducers
• No dose adjustments needed for statins, SSRIs, NSAIDs, PPIs

Chemotherapy Combinations:

• No pharmacokinetic interactions
• Can combine with docetaxel, enzalutamide, abiraterone in prostate cancer
• No interactions with radiation therapy

Other GnRH Agonists/Antagonists:

• Do not combine (redundant mechanism)
• When switching agents, time appropriately

Laboratory Test Interference:

• Suppresses testosterone, estradiol, LH, FSH (therapeutic effect)
• PSA should decline on effective therapy
• No interference with routine chemistry or hematology panels

8. Contraindications

Absolute Contraindications:

Hypersensitivity:

• Known hypersensitivity to triptorelin or any component
• Hypersensitivity to other GnRH agonists (cross-reactivity possible)
• History of anaphylaxis to GnRH analogs

Pregnancy (Category X):

• Contraindicated in pregnancy
• May cause fetal harm
• Pregnancy test required before initiation in women of reproductive potential
• Use effective non-hormonal contraception during therapy

Pediatric Age Restriction:

• Not established in children under 2 years of age (Triptodur)
• Safety and efficacy data insufficient for infants

Relative Contraindications/Precautions:

Prostate Cancer with High Flare Risk:

• Vertebral metastases (spinal cord compression risk)
• Urinary obstruction (acute retention risk)
• Not absolute contraindication but requires:
  • Concurrent antiandrogen therapy
  • Close monitoring during first weeks
  • Consider GnRH antagonist alternative

Cardiovascular Disease:

• FDA warning: Increased CV risk with ADT
• Use with caution in patients with history of MI, stroke, heart failure
• Risk-benefit discussion essential
• Consider alternative treatments or intermittent ADT

Osteoporosis/Fracture Risk:

• Long-term ADT accelerates bone loss
• Baseline and periodic DEXA scans recommended
• Consider bone-protective therapy (bisphosphonates, denosumab)

Diabetes/Metabolic Syndrome:

• ADT associated with hyperglycemia and insulin resistance
• Monitor glucose closely in diabetic patients
• May need to adjust diabetes medications

Seizure Disorders:

• Reports of convulsions with GnRH agonists
• Use with caution in epilepsy patients
• Monitor for increased seizure frequency

Psychiatric History:

• Monitor for mood changes, depression
• Particularly important in pediatric patients
• May exacerbate underlying psychiatric conditions

9. Special Populations

Pediatric Patients (≥2 years):

• Triptodur approved for CPP in children ≥2 years
• Not established in children under 2 years
• Same mechanism of action as in adults
• Initial worsening of pubertal signs possible (weeks 1-2)
• Girls: Menstrual spotting may occur in first 2 months
• Boys: Temporary increase in testosterone effects
• Monitor for pseudotumor cerebri (headache, vision changes)
• Monitor for psychiatric symptoms (emotional lability, aggression)
• Treatment duration: Until appropriate age for puberty (11-13 years typically)

Geriatric Patients:

• Majority of prostate cancer patients are >65 years
• Extensive clinical experience in elderly
• No dose adjustment required
• Higher baseline cardiovascular risk requires careful monitoring
• Increased osteoporosis risk; consider bone protection
• Cognitive effects of ADT may be more pronounced
• Falls and fracture prevention important

Renal Impairment:

• No formal pharmacokinetic studies
• Approximately 42% excreted renally
• Use with caution in severe renal impairment
• No specific dose adjustment established
• Monitor for accumulation-related toxicity

Hepatic Impairment:

• No formal pharmacokinetic studies
• Minimal hepatic metabolism (peptidase-mediated)
• Likely safe in hepatic dysfunction
• No dose adjustment established
• Standard dosing typically used

Pregnancy:

• Category X: Contraindicated
• Must exclude pregnancy before treatment
• Use non-hormonal contraception during therapy
• If pregnancy occurs, discontinue immediately
• Report exposures to manufacturer

Lactation:

• Unknown if excreted in breast milk
• Not recommended during breastfeeding
• Potential for serious adverse reactions in nursing infants
• Discontinue nursing or discontinue drug

Obese Patients:

• Standard dosing regardless of body weight
• IM injection technique may need adjustment for adipose tissue
• Ensure adequate needle length for gluteal injection
• Efficacy maintained across weight ranges

10. Monitoring Parameters

Baseline Assessment (Before Treatment):

Prostate Cancer:

• Serum testosterone level (baseline)
• PSA level (baseline for comparison)
• ECG (QT interval assessment)
• Fasting glucose and HbA1c
• Lipid panel
• DEXA scan if treatment anticipated >6 months
• Assessment of metastatic burden (bone scan, imaging)

Central Precocious Puberty:

• Confirmation of CPP diagnosis (GnRH stimulation test, imaging)
• LH, FSH, testosterone (boys), estradiol (girls)
• Bone age assessment
• Height, weight, pubertal staging (Tanner)
• Baseline ophthalmologic exam (pseudotumor cerebri risk)

Ongoing Monitoring - Prostate Cancer:

Hormone Levels:

• Testosterone: Check at 1 month to confirm castration (<50 ng/dL)
• Recheck every 3-6 months or if clinical progression suspected

Tumor Markers:

• PSA: Check at 3 months, then every 3-6 months
• Rising PSA on therapy indicates castrate-resistant disease

Metabolic Parameters:

• Fasting glucose: Every 3-6 months initially
• HbA1c: Every 6-12 months
• Lipid panel: Annually

Bone Health:

• DEXA scan: Annually during prolonged therapy

Cardiovascular:

• Blood pressure: Each visit
• ECG: Periodically, especially if on QT-prolonging medications

Ongoing Monitoring - Central Precocious Puberty:

Hormone Levels:

• LH, FSH, testosterone/estradiol: Every 3-6 months
• Confirm suppression is maintained

Growth Parameters:

• Height and weight: Every visit
• Growth velocity monitoring
• Bone age: Every 6-12 months
• Pubertal staging (Tanner): Every visit

Safety Monitoring:

• Symptoms of pseudotumor cerebri: Every visit
• Psychiatric symptoms (mood, behavior): Every visit
• Injection site: Inspect at each administration

Treatment Goals:

• Prepubertal LH levels (<0.3 IU/L typically)
• Regression or stabilization of pubertal signs
• Height velocity appropriate for age
• Bone age advancement slowed

11. Cost and Availability

Brand Name Products:

Trelstar (Prostate Cancer):

• Trelstar 3.75 mg (monthly): ~$700-800 per injection (AWP)
• Trelstar 11.25 mg (3-month): ~$2,100-2,400 per injection (AWP)
• Trelstar 22.5 mg (6-month): ~$4,200-4,800 per injection (AWP)
• Manufacturer: Allergan (now AbbVie)

Triptodur (Pediatric CPP):

• Triptodur 22.5 mg (6-month): ~$23,000-25,000 per injection (WAC)
• Manufacturer: Arbor Pharmaceuticals
• Significantly higher cost than adult formulations

Generic Availability:

• No FDA-approved generic triptorelin in the United States (as of 2024)
• Triptorelin generics available in Europe and other regions
• Patent and exclusivity protections limit US generic entry
• Complex depot formulation technology creates manufacturing barriers

Annual Treatment Costs (Approximate - Prostate Cancer):

| Formulation | Doses/Year | Annual Cost | |------

Goal Relevance:

• Managing advanced prostate cancer symptoms and slowing disease progression
• Treating early puberty in children to prevent premature development and preserve adult height potential
• Reducing symptoms and progression of endometriosis, including pain relief and lesion reduction
• Supporting hormone therapy for gender dysphoria by suppressing puberty
• Assisting in fertility treatments by regulating hormone levels for in vitro fertilization
• Providing symptom relief and management for uterine fibroids before surgery

-------|------------|-------------| | 3.75 mg monthly | 13 | ~$9,100-10,400 | | 11.25 mg quarterly | 4 | ~$8,400-9,600 | | 22.5 mg semi-annually | 2 | ~$8,400-9,600 |

The 3-month and 6-month formulations offer comparable annual costs and greater convenience.

Comparison with Alternatives:

Insurance Coverage:

• Generally covered under medical benefit (physician-administered)
• Medicare Part B covers in physician office setting
• Prior authorization typically required
• May require step therapy (oral antiandrogen trial first)
• Specialty pharmacy distribution common

Patient Assistance Programs:

• AbbVie Patient Assistance (Trelstar)
• Income-based eligibility (typically <300-400% FPL)
• Foundation copay assistance programs available
• Oncology-specific financial assistance organizations

12. Clinical Evidence Summary

Prostate Cancer Evidence:

Pivotal Registration Trials:

• Trelstar 3.75 mg achieved castrate testosterone in 91.2% at day 29
• 97.7% achieved castration by day 57
• Maintenance of castration 96.2% through day 253

22.5 mg (6-Month) Formulation Trial:

• N = 120 patients with advanced prostate cancer
• 97.5% achieved castrate testosterone by day 29

• 98% maintained castration at months 6 and 12

• Mean testosterone: 12.8 ng/dL (well below 50 ng/dL cutoff)
• Median PSA reduction: 96.4%

Long-Term Data:

• Consistent efficacy over multiple years of treatment
• Comparable to other GnRH agonists (leuprolide, goserelin)
• No loss of efficacy with extended therapy

Central Precocious Puberty Evidence:

Triptodur Registration Trial:

• Open-label study in children with CPP
• Demonstrated suppression of LH, FSH, and sex steroids
• Pubertal progression arrested
• Height velocity normalized for prepubertal age
• Bone age advancement slowed

Comparison with Leuprolide (2023 Study):

• Retrospective comparison of leuprolide vs. triptorelin in CPP
• Both agents well-tolerated with similar efficacy
• No significant difference in pubertal suppression
• Choice based on availability, dosing preference, and cost

FAERS Pharmacovigilance Analysis (2024):

• 4,018 case reports with triptorelin as primary suspect drug
• 10,117 associated adverse events
• Prostate cancer most common indication (30.44%)
• Precocious puberty second most common (5.82%)
• Safety profile consistent with known GnRH agonist class effects

Meta-Analyses and Guidelines:

• NCCN Guidelines: Triptorelin listed as option for ADT in prostate cancer
• No significant efficacy differences between GnRH agonists
• Choice often based on dosing convenience, cost, and availability
• 6-month formulation particularly valued for patient convenience

13. Comparison with Alternatives

GnRH Agonists (Same Class):

*Eligard room temperature; Lupron Depot refrigerated

Key Differentiators for Triptorelin:

1. Pediatric 6-month option: Triptodur offers longest CPP dosing interval
2. Intramuscular route: May be preferred over subcutaneous by some
3. Equivalent efficacy: >97% castration rates
4. No room temperature option: Requires refrigeration

GnRH Antagonists (Degarelix, Relugolix):

Clinical Decision Factors:

Choose Triptorelin (Trelstar) When:

• 6-month intramuscular option desired for prostate cancer
• Patient already established on triptorelin with good tolerance
• Cost-competitive option acceptable
• Refrigerated storage not problematic

Choose Triptorelin (Triptodur) When:

• Pediatric CPP requiring 6-month dosing
• Minimizing injection frequency important for child/family
• Adequate suppression achieved with semi-annual dosing

Choose Leuprolide When:

• Generic availability important (cost savings)
• 4-month formulation desired (Lupron Depot)
• Subcutaneous administration preferred (Eligard)
• Established pediatric dosing data needed

Choose GnRH Antagonist When:

• Rapid castration needed (symptomatic metastases)
• Flare absolutely contraindicated (spinal cord compression risk)
• Cardiovascular concerns prominent
• Patient preference for oral therapy (relugolix)

14. Storage and Handling

Storage Requirements:

Trelstar (All Formulations):

• Store refrigerated at 2-8°C (36-46°F)
• Protect from light
• Do not freeze
• Keep in original carton until use
• Shelf life: Check expiration date on packaging

Triptodur:

• Store refrigerated at 2-8°C (36-46°F)
• May be stored at room temperature 20-25°C (68-77°F) for up to 90 days
• Do not return to refrigerator after room temperature storage
• Protect from light; keep in original carton

Reconstitution:

Trelstar:

1. Remove vial and pre-filled syringe from refrigerator
2. Allow to reach room temperature before reconstitution (optional, reduces discomfort)
3. Reconstitute lyophilized powder with supplied diluent
4. Shake vigorously to form uniform suspension
5. Withdraw entire contents into syringe
6. Inject immediately after reconstitution

Triptodur:

1. Similar reconstitution with supplied sterile water
2. Mix kit components as directed in prescribing information
3. Shake well to ensure complete suspension
4. Administer within 30 minutes of reconstitution

Administration Technique:

• Route: Intramuscular injection only
• Site: Gluteal muscle (preferred)
• Alternate sites: Deltoid (if permitted by formulation)
• Use adequate needle length to ensure IM delivery
• Inject entire dose; do not divide

Post-Reconstitution Stability:

• Administer immediately after reconstitution
• Do not store reconstituted suspension
• Discard any unused portion
• Single-use vials only

Disposal:

• Dispose of syringes in sharps container
• Follow local regulations for pharmaceutical waste
• Return unused medication to pharmacy if appropriate
• No special hazardous material handling required

Cold Chain Considerations:

• Transport in insulated container with ice packs
• Avoid temperature excursions during shipping
• Verify temperature on receipt
• Do not use if exposed to excessive heat or freezing

15. References

1. Allergan/AbbVie. Trelstar (triptorelin pamoate for injectable suspension) Prescribing Information. Irvine, CA; 2024.

2. Arbor Pharmaceuticals. Triptodur (triptorelin for extended-release injectable suspension) Prescribing Information. Atlanta, GA; 2024.

3. FDA Drug Approval Package: Trelstar Depot (triptorelin pamoate). NDA 020715. 2000.

4. FDA Drug Approval Package: Trelstar LA (triptorelin pamoate). NDA 021288. 2001.

5. FDA Drug Approval Package: Trelstar (triptorelin pamoate) 22.5 mg. NDA 022437. 2010.

6. FDA Drug Approval Package: Triptodur (triptorelin). NDA 208956. 2017.

7. Watson Pharmaceuticals. FDA Approves Watson's Trelstar 22.5 mg. Press Release. March 2010.

8. Heyns CF, Simonin MP, Grosgurin P, et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003;92(3):226-231.

9. Catapano P, Iannelli V, et al. Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study. Front Pediatr. 2023;11:1170025.

10. FDA Drug Safety Communication: Update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. October 2010.

11. Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187-2196.

12. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2024. National Comprehensive Cancer Network.

13. Klein KO, Phillips SA. Review of hormone replacement therapy in girls and adolescents with hypogonadism. J Pediatr Adolesc Gynecol. 2019;32(5):460-468.

14. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752-e762.

15. Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data. Sci Rep. 2025;15:16734.

Paper completed: December 2024 Research paper for educational and clinical reference purposes

Status: PAPER 61 OF 76 COMPLETE

Next Paper: #62 - Histrelin